AbbVie Inc. (NYSE:ABBV) is one of the best cheap stocks to buy for beginners. AbbVie Inc. (NYSE:ABBV) announced on June 2 that the European Commission approved AQUIPTA® for the acute treatment of migraine in adults with or without aura, to be taken as needed. Management stated that the approval marks the second indication for AQUIPTA in the European Union, an oral calcitonin gene-related peptide receptor antagonist. It now holds approval as both an acute treatment option for migraine attacks in adults and as a once-daily preventive treatment option for adults with chronic or episodic migraine who experience four or more migraine days per month.
In another development, AbbVie Inc. (NYSE:ABBV) announced on May 29 authorization by the European Commission (EC) for an expanded label for VENCLYXTO® to include use in combination with acalabrutinib (with or without obinutuzumab), along with use in combination with ibrutinib to treat adult patients with previously untreated chronic lymphocytic leukemia (CLL). Management stated that the expanded label follows the EC’s inclusion of these combinations in the acalabrutinib and ibrutinib labels, with all-oral, fixed-duration combination regimens supporting the current standards of care.
AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.
While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.
-1024x683.jpg "Florida Roads Become a Battleground for Illegal Immigration")
